320 related articles for article (PubMed ID: 27226366)
1. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.
Ali A; Kitchen SG; Chen ISY; Ng HL; Zack JA; Yang OO
J Virol; 2016 Aug; 90(15):6999-7006. PubMed ID: 27226366
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
4. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
[TBL] [Abstract][Full Text] [Related]
7. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.
Chen Y; Jin H; Tang X; Li L; Geng X; Zhu Y; Chong H; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):30-49. PubMed ID: 34821542
[TBL] [Abstract][Full Text] [Related]
8. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
9. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
[TBL] [Abstract][Full Text] [Related]
11. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
[TBL] [Abstract][Full Text] [Related]
12. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
14. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
15. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
16. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
17. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
[TBL] [Abstract][Full Text] [Related]
18. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
